The goal of this study is to determine if a mind-body intervention can help peoplesuffering from symptoms associated with Long COVID. The study is a randomized trialexamining the effectiveness of a mind body intervention in reducing somatic symptoms fromLong COVID in participants as compared to usual care and an active control (second mindbody intervention). The investigators will secondarily investigate whether theintervention alleviates individual somatic complaints and improves daily functioning,relative to usual care and the active control
Not Provided
Behavioral: Mind Body Intervention #1
The mind-body intervention will include regular 1 to 2 hour educational sessions and
lectures, as well as supplemental reading material. In addition, individualized sessions
will be offered each week for students who have additional questions and/or need
additional time with the material.
Inclusion Criteria:
1. Adult (≥ 18 years of age)
2. Infection with Sars-COV2 (i. e., positive antibody, antigen, or PCR testing)
3. Symptoms attributed only to COVID-19 and not to known comorbid disease (e.g., other
infections, cancer, etc)
4. A somatic symptom score ≥ 10 on the SSS-8 questionnaire with involvement of at least
3 domains
5. Symptoms present at least 3 day a week for a minimum of 3 months
6. Willingness to engage in a Mind-Body intervention
Exclusion Criteria:
1. Clear diagnosis of physical disease (e.g. lung fibrosis, myocarditis) not inclusive
of non-specific findings such as mild arthritis
2. Hospitalization in an intensive care unit for acute COVID-19 infections
3. Age greater than 65 years
4. Diagnosis of dementia or similar cognitive impairment
5. Active addiction disorder (e.g. cocaine) that would interfere with study
participation
6. Major psychiatric comorbidity (e.g., schizophrenia). Mild to moderate anxiety and
depression are not considered in this category
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Investigator: Samuel Kukler
Contact: 617-754-2882
skukler@bidmc.harvard.edu
Samuel Kukler
617-754-2882
skukler@bidmc.harvard.edu
Michael Donnino, MD, Principal Investigator
Beth Israel Deaconess Medical Center